A potential treatment strategy for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is dual inhibition of the EGFR and vascular endothelial growth factor (VEGF) signaling pathways.

In the global, randomized, phase III RELAY study, the combination of ramucirumab, a human immunoglobulin G1 monoclonal antibody against VEGF receptor 2, and erlotinib, an EGFR tyrosine kinase inhibitor, demonstrated superior progression-free survival (PFS) versus erlotinib plus placebo in patients with untreated, EGFR-mutated, stage IV NSCLC.

In this exploratory analysis of study data, PFS for the Taiwanese participants of RELAY receiving ramucirumab plus erlotinib versus erlotinib plus placebo was consistent with that in the overall RELAY population, with no new safety signals.